Rezolute (RZLT) Income from Continuing Operations (2012 - 2026)
Rezolute's (RZLT) quarterly Income from Continuing Operations came in at 16171000.0 in Q1 2026, up 14.48% year-on-year from 14126184.71 in Q1 2025, and up 28.99% quarter-over-quarter from 22774000.0 in Q4 2025.
Rezolute (RZLT) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Rezolute has disclosed Income from Continuing Operations across 15 years of filings, most recently posting 16171000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 16171000.0, up 14.48% year-over-year; the trailing twelve-month figure through Mar 2026 was 81485000.0 (down 13.07% YoY), and the FY2025 annual result was 74412000.0, down 13.51% from the prior year.
- Income from Continuing Operations came in at 16171000.0 for Q1 2026 at Rezolute, up from 22774000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9818000.0 in Q3 2022 to a low of 24405000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 15363000.0 (2024), against an average of 15956176.47.
- Across the five-year window, Income from Continuing Operations plunged 104.34% in 2022 and gained 14.48% in 2026, its largest moves.
- Rezolute's Income from Continuing Operations stood at 13543000.0 in 2022, then declined by 2.57% to 13891000.0 in 2023, then fell by 13.28% to 15736000.0 in 2024, then plunged by 44.73% to 22774000.0 in 2025, then advanced by 28.99% to 16171000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16171000.0 (Q1 2026), 22774000.0 (Q4 2025), and 18135000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Rezolute | 520.13 Mn | 520.13 Mn | - | -16.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.17 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -18.91 Mn |
| Dec 31, 2024 | -15.74 Mn |
| Sep 30, 2024 | -15.36 Mn |
| Jun 30, 2024 | -22.06 Mn |
| Mar 31, 2024 | -15.09 Mn |
| Dec 31, 2023 | -13.89 Mn |
| Sep 30, 2023 | -14.51 Mn |
| Jun 30, 2023 | -12.76 Mn |
| Mar 31, 2023 | -15.66 Mn |
| Dec 31, 2022 | -13.54 Mn |
| Sep 30, 2022 | -9.82 Mn |
| Jun 30, 2022 | -11.23 Mn |
| Mar 31, 2022 | -11.20 Mn |
| Dec 31, 2021 | -12.59 Mn |
| Sep 30, 2021 | -8.08 Mn |
| Jun 30, 2021 | -6.64 Mn |